ALONE- AF ランダム化臨床試験
Daehoon Kim1, Jaemin Shim2, Eue-Keun Choi3
1Division of Cardiology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea.
JAMA
|August 31, 2025
まとめ
動脈不良が再発しない患者において,口服抗凝固薬の投与を中止すると,脳卒中および出血のリスクが低下する可能性があります. この戦略は,抗凝固治療の継続と比較して,複合的な結果の減少を示した.
科学分野:
- 心臓病科
- 臨床試験
- アトリアルフィブリレーションの管理
背景:
- 心房細動 (AF) の長期抗凝固策に関するランダム化臨床試験データは限られている.
- AF切除を受けた患者は,注意深い管理を必要とする脳卒中の危険因子を持っていることが多い.
研究 の 目的:
- 抗凝固剤の投与を中止した患者の臨床結果と,抗凝固剤の投与を継続した患者の臨床結果を比較する.
- この特定の患者集団におけるOAT停止の有効性と安全性を評価する.
主な方法:
- 韓国で実施された840人の患者によるランダム化臨床試験です.
- 最低1つの脳卒中リスク因子 (CHA2DS2- VAScスコア) とAF再発のない患者は,OAT (直接経口抗凝固薬) を中止または継続するために1対1でランダム化されました.
- 主なアウトカム:脳卒中,全身栓塞,大出血の複合体 2年.
主要な成果:
- 主要コンポジットアウトカムは,OATを中止した患者の0. 3%と,OATを継続した患者の2. 2%で発生した (P=0. 02).
- OATの中止は,低血性脳卒中の発生率 (0. 3% 対 0. 8%) と著しく低い大出血率 (0% 対 1. 4%) を示した.
- この研究では,平均CHA2DS2- VAScスコアが2. 1で,主に心筋梗塞性AFの患者 (67. 6%) が参加した.
結論:
- 動脈不全の再発のない選択された患者でOATを中止することは,脳卒中,全身栓塞,および大出血の複合的な結果のリスクが低いと関連しています.
- この戦略は,この集団の長期的な管理のためのより安全な代替案を提供することができ,さらなる調査を正当化します.
関連する概念動画
01:29Venous Thrombosis III: Interprofessional Care
22
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
22
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
889
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
889
01:26Cardiac Catheterization IV: Nursing Management
193
Nursing responsibilities before cardiac catheterization include:Assess for allergies and establish baseline health status.Before cardiac catheterization, assess the patient for allergies to contrast dye. Perform a comprehensive baseline assessment, including vital signs, heart and breath sounds, and a neurovascular assessment of the extremities, noting distal pulses, skin color, and temperature. Instruct the patient to fast for 8-12 hours before the procedure. Evaluate baseline laboratory...
193
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K
01:28Cardiac Catheterization I: Pre-Procedure Overview
153
Cardiac catheterization is an invasive diagnostic technique used to identify and evaluate structural and functional diseases of the heart and major blood vessels. This technique diagnoses congenital heart disease, coronary artery disease, valvular heart disease, and coronary spasms and assesses ventricular function. It helps guide treatment decisions, including the need for revascularization procedures like percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) and...
153